ImmUniverse Advances Multi-Omics Research and Patient-Centred Innovation

As the ImmUniverse project approaches its conclusion, the consortium is reflecting on several years of collaborative research dedicated to improving the understanding and management of immune mediated diseases, with a particular focus on ulcerative colitis and atopic dermatitis.

Bringing together leading experts from academia, industry, and patient organisations across Europe, ImmUniverse has generated valuable insights into disease mechanisms, treatment response, and biomarker discovery through the integration of clinical data with cutting edge multi-omics technologies.

Driving Scientific Progress

ImmUniverse has delivered major advances across several areas:

• Integrated multi-omics approaches: By combining genomics, proteomics, metabolomics, and clinical data, the project has enabled a more comprehensive understanding of disease mechanisms and treatment response.
• Biomarker discovery and validation: New candidate biomarkers have been identified to help distinguish responders from non responders and to better monitor disease activity.
• Innovative diagnostic and research technologies: Approaches such as liquid biopsy and tissue microenvironment analysis are opening new possibilities for less invasive and more precise disease monitoring.
• Robust data infrastructure: A secure and interoperable data ecosystem has been established to connect clinical and molecular data, enabling advanced analysis across cohorts
• Deeper biological insights: Multi layer analyses have linked molecular signals to underlying biological processes, including inflammation, immune regulation, and tissue remodeling.

From Data to Long-Term Impact

Beyond the scientific findings, ImmUniverse has created a substantial resource of high quality clinical and molecular data that will continue to support future research.

Current efforts focus on finalising scientific publications, ensuring continued accessibility of curated datasets, establishing sustainable data governance models, and enabling future collaborations that build upon the project's achievements.

The consortium is committed to ensuring that the knowledge, tools, and resources generated through ImmUniverse remain valuable and accessible beyond the project's formal end.

Strengthening Patient-Centred Research

Patient involvement has been a key element of the project, with important lessons learned along the way. Consortium partners and patient organisations highlighted the need for:

• Earlier and more continuous patient involvement
• Clear and accessible communication
• Stronger integration of patient perspectives into study design

Collaboration as a Foundation

The success of ImmUniverse has been built on strong collaboration across disciplines, sectors, and countries. Despite challenges such as the COVID 19 pandemic and the complexity of coordinating large-scale research activities, consortium partners maintained momentum and delivered meaningful scientific progress. The initiative demonstrates the value of bringing together expertise from academia, industry, healthcare, technology development, and patient advocacy to address complex health challenges.

Looking Ahead

While the project is entering its final phase, the work continues: Multiple publications are currently in preparation, additional analyses are ongoing, and consortium partners remain committed to translating findings into clinical relevance and future innovation. The project's legacy will extend beyond its formal end, supporting future advances in precision medicine and improving outcomes for people living with immune mediated diseases.

Final Meeting in Milan

As part of this closing phase, consortium partners recently met at Humanitas University in Milan to review progress, align on next steps, and strengthen collaboration. The meeting concluded with a social evening exploring the city through a food tour, offering participants a moment to reflect on the journey and the connections built over the years.